Potent and selective aromatase inhibitor: In vitro and in vivo studies with s-triazine derivative SEF19

Endocrine Research

Volumn 23, Issue 1-2, 1997, Pages 1-13

  Takahashi, M ^a   Kayo, T ^a   Karakida, T ^a   Nakagawa, S ^a   Kato, M ^a   Matsuno, S ^a   Koide, Y ^a   Sakato, M ^a   Kawashima, S ^a  

^a ZENYAKU KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 IMIDAZOLYL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (IMIDAZOL 1 YL) 4,6 DIMORPHORINO 1,3,5 TRIAZINE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); ESTROGEN RECEPTOR; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; STEROID 21 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN METABOLISM; FEMALE; HUMAN; MUSCLE HYPERTROPHY; MYOMETRIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SWINE;

EID: 0030905739     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1080/07435809709031838     Document Type: Article

References (34)

1. Lønning PE, Kvinnsland S, Thorsen T, and Ueland PM, 1987 Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clin Pharmacokinet 13:393-406.
2. Dexter RN, Fishman LM, Ney RL, Liddle GW, 1967 Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: Studies of the mechanism of action. J Clin Endocr 27:473-480.
3. Cohen MP, 1968 Aminoglutethimide inhibition of adrenal desmolase activity, Proc Soc Exper Biol Med 127:1086-1900.
4. Gower DB, 1974 Modifiers of steroid-hormone metabolism: A review of their chemistry, biochemistry and clinical application. J Steroid Biochem 5:501-523.
5. Santen RJ, 1981 Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Res Treat 1:183-202.
6. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL, Coombes RC, 1987 Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 47:1957-1961.
7. Cunningham D, Powles TJ, Dowsett M, Hutchinson G, Brodie AMH, Ford HT, Gazet J-C, Coombes RC, 1987 Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol 20:253-255.
8. Iino Y, Sugamata N, Susumu N, Owada S, Tago T, Sato H, Yokoe T, Maemura M, Morishita Y, Horiuchi R, 1991 Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[α]anthracene-induced mammary tumors in rats. Jpn J Clin Oncol 21:153-159.
9. Schieweck K, Bhatnagar AS, Batzl C, Lang M, 1993 Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Molec Biol 44:633-636.
10. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Fitzsimmons S, Sanders SI, Santen RJ, 1990 A phase I trial of CGS 16949A. Cancer 65:1279-1285.
11. Raats JI, Falkson G, Falkson HC, 1992 A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 10:111-116.
12. Brodie AMH, 1994 Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Molec Biol 49:281-287.
13. Dowsett M, Smithers D, Moore J, Trunet PF, Coombes RC, Powles TJ, Rubens R, Smith IE, 1994 Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer 30A: 453-1458.
14. Tanino H, Kubota T, Yamada Y, Koh J, Takeuchi T, Kase S, Furuawa T, Takahashi M, Fukuda S, Ogose N, Komatsu T, Sakato M, Kitajima M, Sakurai T, Naito Y, Hoffman RM, 1993 A newly developed haxamethymelamine derivative, SAE9 with both antitumor and aromatase-inhibitory activity. Anticancer Res 13:623-626.
15. Matsuno T, Kato M, Tsuchida Y, Takahashi M, Yaguchi S, Terada S, 1996 Synthesis of imidazolyl-1,3,5-triazine derivatives and their aromatase inhibitory activity. Chem Pharmac Bull in press.
16. Yuan P-M, Nakajin S, Haniu M, Shinoda M, Hall PF, Shively JE, 1983 Steroid 21-hydroxylase (cytochrome P-450) from porcine adrenocortical microsomes: Microsequence analysis of cysteine-containing peptides. Biochemistry 22:143-149.
17. Kimura T, 1968 Biochemical aspect of iron-sulfur linkage in non-heme iron protein, with special reference to "adrenodoxin" In: Neilands J. B., Nyholm RS, Reinen D, and Williams RJP (eds) Structure and Bonding, vol. 5, Springer-Verlag, Berlin, pp. 1-40.
18. Thompson Jr. EA and Siiteri PK, 1974 Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 249:5364-5372.
19. Numazawa M, Mutsumi A, Asano N, Ito Y, 1993 A time-dependent inactivation of aromatase by 19-substituted androst-4-ene-3,6,17-triones. Steroids 58:40-46.
20. Shikita M, Hall PF, 1974 The Stoichiometry of the conversion of cholesterol and hydroxycholesterols to pregnenolone (3β-hydroxypregn-5-en-20-one) catalyzed by adrenal cytochrome P-450. Proc Nat Acad Sci USA 71:1441-1445.
21. Nakajin S, Hall PF, 1981 Microsomal cytochrome P-450 from neonatal pig testis. J Biol Chem 256:3871-3876.
22. Shizuta Y, Kawano T, Mitsuuci Y, Toda K, Miyahara K, Ichikawa Y, Imura H, Ulick S, 1992 Molecular genetic studies on the biosynthesis of aldosterone in humans. J Steroid Biochem Molec Biol 43:981-987.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, 1951 Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Sakoda M, Hiromi K, 1976 Determination of the best-fit values of kinetic parameters of the Michaelis-Menten equation by the method of least squares with the Taylor expansion. J Biochem 80:547-555.
25. Nakajin S, Hall PF, 1986 Purification to homogeneity of aromatase from human placenta. Biochem Biophys Res Commun 134:704-710.
26. 44-androstene-3,17-dione to estrone by endocrine tissue. Biochim Biophys Acta 17:441-442.
27. Santen RJ, Samojlik E, Demers L, Badder E, 1980 Adrenal of male dog secretes androgens and estrogens. Am J Physiol 239:E109-E112.
28. Lamberts SWJ, Bruining HA, Marzouk H, Zuiderwijk J, Uitterlinden P, Blijd JJ, Hackeng WHL, de Jong FH. 1989 The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab 69:896-901.
29. Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A. 1989 Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab 68:99-106.
30. Dowsett M, Stein RC, Mehta A, Coombes RC. 1990 Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocr 32:623-634.
31. Häusler A, Monnet G, Borer C, Bhatnagar AS, 1989 Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J Steroid Biochem 34:567-570.
32. Steel RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ, 1987 In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids 50:147-161.
33. Bhatnagar AS, Häusler A, Schieweck K, 1990 Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J Enz Inhibit 4:179-186.
34. Selvaraj N, Shetty G, Vijayalakshmi K, Bhatnagar AS, Moudgal NR, 1994 Effect of blocking oestrogen synthesis with a new generation aromatase inhibitor CGS 16949A on follicular maturation induced by pregnant mare serum gonadotrophin in the immature rat. J Endocr 142:563-570.